Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sarepta Therapeutics Inc Sees FY 2012 Revenue Guidance At Low End Of Prior Range; Reaffirms FY 2012 Earnings Guidance
Sarepta Therapeutics Inc announced that for fiscal 2012, it expects revenue will be at the lower end of the previously issued guidance of $37-$43 million. Additionally, operating loss is expected to be within the previous disclosed range of $25-$30 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $43 million and EBIT of $(25) million for fiscal 2012.
Latest Developments for Sarepta Therapeutics Inc
- Sarepta Therapeutics Inc Issues FY 2013 Guidance Below Analysts' Estimates
- Sarepta Therapeutics Inc Announces Pricing Of $125 Million Public Offering Of Common Stock
- Sarepta Therapeutics Inc Announces Proposed Public Offering Of Common Stock
- Sarepta Therapeutics Inc Announces Continued Benefit On Walking Test Through 62 Weeks In Phase IIb Open-Label Extension Study of Eteplirsen In Duchenne Muscular Dystrophy
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters